U.S. Auto Stock News

In early December 2025, Polaris Slingshot launched its 2026 model-year lineup, including a limited-edition Grand Touring trim, new premium iridescent paint schemes, upgraded wheel designs, and an optional subscription-based RIDE COMMAND+ connected services package. This refresh pushes Slingshot further into higher-end, feature-rich territory, potentially reinforcing Polaris’ premium positioning and deepening customer engagement through digital services. We’ll now examine how the...

CSX (CSX) shares have quietly climbed in the past month, and that move has investors asking whether this rail giant’s recent momentum reflects improving fundamentals or simply a broader market tailwind. See our latest analysis for CSX. Zooming out, CSX’s recent climb to a share price of $37.09 extends a steady upward trend, with a roughly mid-teens year to date share price return and a double digit one year total shareholder return that together signal gradually improving sentiment rather...

If you are wondering whether VeriSign at around $242 a share is still worth considering, or if the big gains are already behind it, this breakdown is for you. Despite being down 3.0% over the last week and 2.2% over the past month, the stock is still up 18.1% year to date and 22.2% over the last year, which quietly signals resilient long term momentum. Recently, investors have been refocusing on VeriSign's core role in internet infrastructure and its long term, contract based revenue. This...

Rumble (RUM) is putting fresh attention on its subscription strategy after announcing that the highly anticipated “MF Mania, The Fight Before Christmas” boxing spectacle will stream exclusively on Rumble Premium on December 20, 2025. See our latest analysis for Rumble. The announcement comes after a choppy stretch for investors, with a 1 month share price return of 17.92 percent but a year to date share price return of negative 41.61 percent. At the same time, the 1 year total shareholder...

Kyndryl Holdings (NYSE:KD) just rolled out its Quantum Safe Assessment service, a new cybersecurity offering that helps large enterprises map their cryptographic weak spots and plan a gradual shift toward quantum resistant security standards. See our latest analysis for Kyndryl Holdings. The launch of Quantum Safe Assessment lands at an interesting moment for Kyndryl, with the share price at $27.47 and a recent 1 month share price return of 5.41% following a much weaker year to date. At the...

Wondering if Natera is still attractive after such a massive run, or if the easy money has already been made? Let us unpack what the market is really pricing in here. The stock has cooled slightly over the last week, down 3.7%, but that comes after a strong 12.8% gain over 30 days and an impressive 45.2% return year to date, building on a huge 511.2% gain over 3 years. Recent momentum has been driven by growing investor enthusiasm around Natera's core genetic testing platforms and their...

Middleby (MIDD) just caught fresh attention after Jefferies shifted to a Buy rating, pointing to momentum in its Commercial Foodservice business, healthier margins, and ongoing support from share repurchases and insider buying. See our latest analysis for Middleby. The Jefferies upgrade seems to have lit a fire under the stock, with a 1 day share price return of 9.27 percent and a 7 day share price return of 17.56 percent, even though the 1 year total shareholder return is still slightly...

On 10 December 2025, Ruter and Holo announced a partnership with MOIA to deploy Volkswagen’s ID. Buzz AD in Oslo’s Groruddalen suburb from as early as spring 2026, using the second-generation Mobileye Drive self-driving system built on the EyeQ 6H chip as part of an on-demand autonomous transport service. This move, following multi‑year trials in challenging Norwegian winter conditions, positions Mobileye Drive as a core technology for one of Europe’s first series-production Level 4...

In early December 2025, BKV Corporation completed a follow-on equity offering of US$156,000,000, issuing 6,000,000 common shares at US$26 each, reflecting a US$1.17 per-share discount to the prior price range. The deal coincided with upbeat analyst sentiment and upward earnings estimate revisions, suggesting investors viewed the capital raise as supportive of BKV’s growth plans rather than dilutive risk. Next, we’ll examine how this upbeat analyst sentiment around BKV’s successfully...

If you have been wondering whether Citizens Financial Group is still a bargain after its latest run up, you are not alone. This article is going to unpack exactly what you might be paying for at today’s price. The stock has climbed 5.0% over the last week, 11.7% over the past month, and is now up 34.1% year to date, building on a 31.3% 1 year gain and more than doubling investors’ money over 5 years with a 104.4% total return. Recent moves have been driven by a mix of improving sentiment...

ExlService Holdings (EXLS) has quietly slipped this year, with the stock down around 12% over the past year even as revenue and net income each grew roughly 11% annually, creating an interesting disconnect. See our latest analysis for ExlService Holdings. Despite this weak patch, the mood around ExlService has steadied a bit. A 1 month share price return of 2.88 percent has lifted the stock to about 40.77 dollars, while its 5 year total shareholder return of 140.08 percent shows long term...

Thermo Fisher Scientific (TMO) has been back in the spotlight after a wave of upbeat coverage from major banks, tying its stock story to improving life sciences demand and fresh bioprocessing expansion across Asia. See our latest analysis for Thermo Fisher Scientific. Those Asia bioprocessing moves and the new cardiac risk test partnership have arrived just as sentiment is turning, with Thermo Fisher’s share price up 16.8 percent over 90 days and its 1 year total shareholder return at 7.8...

Biohaven Ltd. recently presented clinical safety and efficacy data from its novel Trop2-directed antibody-drug conjugate BHV-1510, in combination with Regeneron’s anti-PD-1 cemiplimab, at the 2025 ESMO Immuno-Oncology Congress in London, showing meaningful response rates and manageable safety across several tumor types. The data, including strong objective response rates in non-small cell lung, endometrial, urothelial and triple negative breast cancers, underscores Biohaven’s growing...

PepsiCo (PEP) just laid out a sweeping turnaround plan with activist investor Elliott that combines price cuts, a leaner US product lineup, and aggressive cost savings, and JPMorgan has already responded by turning more optimistic on the stock. See our latest analysis for PepsiCo. The flurry of activism news, refreshed guidance for 2025 and 2026, and even splashy marketing moves like the Mercedes F1 partnership help explain why PepsiCo’s recent 30 day share price return of 4.96% contrasts...

In late November and early December 2025, Rockwell Automation announced cloud-native upgrades to its Manufacturing Execution System portfolio and deepened its Saudi presence via a collaboration with alfanar, including a new automation panel manufacturing zone in Riyadh serving critical infrastructure projects like the Saudi Water Authority. These moves highlight Rockwell Automation’s push to embed its technology at the core of digitally enabled industrial operations, linking software,...

Lockheed Martin (LMT) has been quietly grinding higher, with the stock up about 4% over the past week and 2% over the past month, even as year to date returns remain slightly negative. See our latest analysis for Lockheed Martin. At around $467.94 per share, Lockheed Martin is edging higher again, with recent share price gains hinting that sentiment may be turning after a weaker year to date, even though the five year total shareholder return still looks solid. If this renewed interest in...

GE HealthCare Technologies (GEHC) has quietly pushed higher recently, with the stock up about 15% over the past month and roughly 8% in the past 3 months, outpacing many healthcare peers. See our latest analysis for GE HealthCare Technologies. Zooming out, the stock’s roughly 15% 1 month share price return and 7.8% year to date share price return, alongside a modest 1 year total shareholder return of just over 2%, point to momentum that has picked up recently rather than been sustained all...

Wondering if Medical Properties Trust at around $5.50 is a bargain or a value trap? You are not alone. This stock has become a lightning rod for income investors trying to separate recovery potential from real risk. After a brutal multi year slide, the shares are still down 39.6% over 3 years and 61.6% over 5 years, but they have bounced 37.1% year to date and 43.6% over the last year, including an 11.1% gain in the past month despite a minor 2.0% pullback this week. That rebound has played...

D.R. Horton (DHI) shares inched higher in the latest session, extending a mixed stretch where gains this month contrast with weaker performance over the past 3 months and prompting a closer look at what the market is pricing in. See our latest analysis for D.R. Horton. With the share price now around $155, D.R. Horton’s 1 month share price return of 7.4 percent and modest 1 year total shareholder return of 2.2 percent suggest momentum is rebuilding after a choppy few months. If this move has...

In recent months, Sociedad Química y Minera de Chile placed UF10 million in series S bonds for general corporate purposes and debt refinancing, while also reporting record third-quarter sales amid recovering demand and pricing. At the same time, the company outlined a US$2.70 billion investment plan through 2027 to expand lithium carbonate capacity and deepen its partnership with state miner Codelco in the Atacama salt flat, underscoring an intensified focus on long-term lithium...

If you are wondering whether Heidrick & Struggles International is still a smart buy after such a strong run, you are not alone. This is exactly what we are going to unpack here. The stock has climbed 33.9% year to date and is up 30.4% over the last year, while longer term holders have seen gains of 108.8% over 3 years and 122.8% over 5 years, all from a recent close of $59.01. Those gains have come as investors have warmed to the company’s positioning in higher value advisory and leadership...

Trane Technologies (TT) has been treading water lately, with the stock roughly flat over the past year after a strong multi year run, even as revenue and net income continue to grow steadily. See our latest analysis for Trane Technologies. At around a 7 percent year to date share price return and a powerful five year total shareholder return of just over 200 percent, Trane’s recent consolidation near 399.14 looks more like a pause after a long rally than a trend break. Investors are...

Assessing AbbVie after a strong run AbbVie (ABBV) has quietly delivered solid gains this year, and with the stock recently closing around 225 dollars, investors are asking whether the current momentum still lines up with fundamentals. See our latest analysis for AbbVie. The 1 year total shareholder return of 33.65 percent, alongside a year to date share price return of 25.49 percent with the stock now at 225.18 dollars, suggests momentum is still building rather than fading. If AbbVie’s run...

On 9 December 2025, Rocket Companies presented at the Goldman Sachs 2025 U.S. Financial Services Conference, updating investors on how its acquisitions and technology platform are reshaping its nationwide mortgage and real estate services. Management highlighted that early Redfin integration is already driving more Redfin buyers to choose Rocket mortgages and supporting very strong growth in home equity lending, underscoring the company’s push to deepen customer engagement across its...